ClinicalTrials.gg
RecruitingNCT04532190FAST-ADHDUpdated May 14, 2026

Finding Alternatives to Standard Treatment for Attention-Deficit Hyperactivity Disorder

An interventional study of rTMS in Attention-Deficit/Hyperactivity Disorder (ADHD), sponsored by University of Calgary. Recruiting at 1 site in Canada. Open to participants aged 9 Years to 15 Years. Per ClinicalTrials.gov, last updated 2026-05-14.

Sponsored by University of Calgary · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
9 Years to 15 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 85 studies in Attention Deficit Disorder with Hyperactivity with a site in Canada — 12 open to participants now, 16 under way, none of them phase 3. Attention Deficit Disorder with Hyperactivity · Canada.

Planned enrollment
63rd of 72
30 · median 108
Started
2026
with 3 others
No phase
24 of 85
4 open now
Primary completion
2027-12
later than 12 of 15 live
Registered
64th of 85
by date
Lead sponsor
4 of 85
University of Calgary

Among the 85 studies in Attention Deficit Disorder with Hyperactivity with a site in Canada, this one is the 63rd largest by planned enrollment of the 72 interventional ones that give a count, is one of 4 that started in 2026, is one of 24 with no phase, reaches primary completion later than 12 of the 15 other live ones, and was the 64th registered.

Attention Deficit Disorder with Hyperactivity

1,821 studies on the registry are indexed under Attention Deficit Disorder with Hyperactivity; 297 are open to participants now.

Browse Attention Deficit Disorder with Hyperactivity studies →

Open to participants now

12 of the 85 studies in Attention Deficit Disorder with Hyperactivity with a site in Canada are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 200 Attention Deficit Disorder with Hyperactivity studies recruiting now, 26 (13%) set no upper age limit and 169 (85%) stop at 75 or younger; 141 take children under 18; 55 take healthy volunteers.

This study: 9 Years to 15 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 85 studies in Attention Deficit Disorder with Hyperactivity with a site in Canada, or all of them as a file.
02

Study summary

Attention-Deficit/Hyperactivity Disorder (ADHD) is characterized by poor attention, impulsivity, hyperactivity and emotional-motivational dysregulation. Here, we will test if theta burst repetitive transcranial magnetic stimulation (rTMS) can reduce the symptoms of ADHD.

Read the detailed description

Background \& Rationale Attention-Deficit/Hyperactivity Disorder (ADHD) is characterized by poor attention, impulsivity, hyperactivity and emotional-motivational dysregulation. It has an estimated prevalence of 5% in children. Usually, ADHD in children is treated with stimulant medications, such as methylphenidate. However, these pharmacotherapy treatments have numerous unwanted side effects, including sleep disturbances, appetite changes, and emotional lability, and do not prove to be effective in every case.

A promising and alternative option for reducing ADHD symptoms is non-invasive brain stimulation. Repetitive transcranial magnetic stimulation (rTMS) is a form of non-invasive brain stimulation which involves the application of a magnetic field to the skull to change the behaviour and function of underlying brain areas. In turn, rTMS leads to positive long-term changes in neurochemical activity, and while studies are limited, some have shown that rTMS can reduce ADHD symptoms in adolescents with ADHD.

Methods Design: Open label TMS trial Primary Outcome: To examine the effect of active rTMS to the right prefrontal cortex on attention as measured by the TEACh-2

Outline:

  1. Baseline Assessment (MRI Scan, assessment scales, neuropsychological testing)
  2. rTMS intervention: 5 / week for 4 weeks.
  3. Post-intervention Assessment (MRI Scan, assessment scales, neuropsychological testing).
03

Conditions studied

  • Attention-Deficit/Hyperactivity Disorder (ADHD)

Keywords

  • Attention-Deficit/Hyperactivity Disorder (ADHD
  • Repetitive transcranial magnetic stimulation (rTMS)
04

Who can participate

Ages eligible
9 Years to 15 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosis of ADHD
  2. 9-15 years old
  3. IQ greater than 80
  4. English fluency (to enable consent/assent)
  5. If on medication, must have been on the same type and dosage for at least 3 months.

Exclusion criteria

Exclusion Criteria:

  1. Diagnosis of mania, psychosis, or bipolar disorder
  2. Impediments to TMS or MRI (i.e. metal implants in body)
  3. Prior electroconvulsive therapy or vagus nerve stimulation
  4. Diagnosis of Autism Spectrum Disorder.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Active rTMS

    Active repetitive TMS

    Device: rTMS

Interventions

  • DevicerTMS

    Repetitive transcranial magnetic stimulation (rTMS)

06

What researchers measure

Primary outcomes

  1. TEACH-2

    Test of everyday attention in children - 2. Direct assessment of attention abilities in children.

    Time frame: Baseline to week 5

Secondary outcomes

  1. SNAP-18

    Parent reporting of ADHD symptom severity

    Time frame: 5 weeks and 52 weeks.

  2. PedsQL

    Self reporting of quality of life

    Time frame: Baseline to week 5

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — If we do make individual participant data (IPD) available to other researchers it will be in keeping with local provincial laws on health information privacy. Data (if available) will be provided upon request.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Dec 2027, 21 months after the start.

Of 480 non-industry interventional studies with no phase under Attention Deficit Disorder with Hyperactivity, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 43. This study's planned 21 months is below that.

Counting every sponsor, half of 511 studies reached it within 23 months; a quarter within 11 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 25, 2020
First posted
Aug 31, 2020
StartActual
Mar 1, 2026
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2027
Last update
May 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04532190
Responsible party
Kara Murias (Assistant Professor, University of Calgary) — Principal investigator
First posted
Aug 31, 2020
Start date
Mar 1, 2026
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
May 14, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion